Literature DB >> 17060470

Protective and immunochemical activities of monoclonal antibodies reactive with the Bacillus anthracis polypeptide capsule.

Thomas R Kozel1, Peter Thorkildson, Suzanne Brandt, William H Welch, Julie A Lovchik, David P AuCoin, Julpohng Vilai, C Rick Lyons.   

Abstract

Bacillus anthracis is surrounded by a polypeptide capsule composed of poly-gamma-d-glutamic acid (gammaDPGA). In a previous study, we reported that a monoclonal antibody (MAb F26G3) reactive with the capsular polypeptide is protective in a murine model of pulmonary anthrax. The present study examined a library of six MAbs generated from mice immunized with gammaDPGA. Evaluation of MAb binding to the capsule by a capsular "quellung" type reaction showed a striking diversity in capsular effects. Most MAbs produced a rim type reaction that was characterized by a sharp increase followed directly by a decrease in refractive index at the capsular edge. Some MAbs produced a second capsular reaction well beneath the capsular edge, suggesting complexity in capsular architecture. Binding of MAbs to soluble gammaDPGA was assessed by a fluorescence perturbation assay in which a change in the MAb intrinsic fluorescence produced by ligand binding was used as a reporter for antigen-antibody interaction. The MAbs differed considerably in the complexity of the binding curves. MAbs producing rim type capsule reactions typically produced the more complex binding isotherms. Finally, the protective activity of the MAbs was compared in a murine model of pulmonary anthrax. One MAb was markedly less protective than the remaining five MAbs. Characteristics of the more protective MAbs included a relatively high affinity, an immunoglobulin G3 isotype, and a complex binding isotherm in the fluorescence perturbation assay. Given the relatively monotonous structure of gammaDPGA, the results demonstrate a striking diversity in the antigen binding behavior of gammaDPGA antibodies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17060470      PMCID: PMC1828423          DOI: 10.1128/IAI.01133-06

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  38 in total

1.  Capsular reactions of Cryptococcus neoformans with polyspecific and oligospecific polyclonal anticapsular antibodies.

Authors:  T C MacGill; R S MacGill; T R Kozel
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

2.  Capsule synthesis by Bacillus anthracis is required for dissemination in murine inhalation anthrax.

Authors:  Melissa Drysdale; Sara Heninger; Julie Hutt; Yahua Chen; C Rick Lyons; Theresa M Koehler
Journal:  EMBO J       Date:  2004-12-16       Impact factor: 11.598

3.  Immunogenicity and protective efficacy of Bacillus anthracis poly-gamma-D-glutamic acid capsule covalently coupled to a protein carrier using a novel triazine-based conjugation strategy.

Authors:  Joseph Joyce; James Cook; Donald Chabot; Robert Hepler; Wesley Shoop; Qiuwei Xu; Thomas Stambaugh; Miguel Aste-Amezaga; Su Wang; Lani Indrawati; Mark Bruner; Arthur Friedlander; Paul Keller; Michael Caulfield
Journal:  J Biol Chem       Date:  2005-11-17       Impact factor: 5.157

4.  Antibodies to CD40 induce a lethal cytokine cascade after syngeneic bone marrow transplantation.

Authors:  J A Hixon; B R Blazar; M R Anver; R H Wiltrout; W J Murphy
Journal:  Biol Blood Marrow Transplant       Date:  2001       Impact factor: 5.742

5.  Bacillus anthracis CapD, belonging to the gamma-glutamyltranspeptidase family, is required for the covalent anchoring of capsule to peptidoglycan.

Authors:  Thomas Candela; Agnès Fouet
Journal:  Mol Microbiol       Date:  2005-08       Impact factor: 3.501

6.  Immunochemical studies on the poly-gamma-D-glutamyl capsule of Bacillus anthracis. VI. The in vivo fate and distribution to immunized rabbits of the polypeptide in immunogenic and nonimmunogenic forms.

Authors:  G E Roelants; L F Whitten; A Hobson; J W Goodman
Journal:  J Immunol       Date:  1969-11       Impact factor: 5.422

7.  Identification of a novel gene, dep, associated with depolymerization of the capsular polymer in Bacillus anthracis.

Authors:  I Uchida; S Makino; C Sasakawa; M Yoshikawa; C Sugimoto; N Terakado
Journal:  Mol Microbiol       Date:  1993-08       Impact factor: 3.501

8.  A dually active anthrax vaccine that confers protection against both bacilli and toxins.

Authors:  Gi-Eun Rhie; Michael H Roehrl; Michael Mourez; R John Collier; John J Mekalanos; Julia Y Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-05       Impact factor: 11.205

9.  Protective murine monoclonal antibodies to Cryptococcus neoformans.

Authors:  J Mukherjee; M D Scharff; A Casadevall
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

10.  Induction of opsonic antibodies to the gamma-D-glutamic acid capsule of Bacillus anthracis by immunization with a synthetic peptide-carrier protein conjugate.

Authors:  Taia T Wang; Patricia F Fellows; Terrance J Leighton; Alexander H Lucas
Journal:  FEMS Immunol Med Microbiol       Date:  2004-04-09
View more
  28 in total

Review 1.  Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.

Authors:  S Ramasamy; C Q Liu; H Tran; A Gubala; P Gauci; J McAllister; T Vo
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

2.  Pre- and postexposure protection against virulent anthrax infection in mice by humanized monoclonal antibodies to Bacillus anthracis capsule.

Authors:  Zhaochun Chen; Rachel Schneerson; Julie Lovchik; C Rick Lyons; Huaying Zhao; Zhongdong Dai; Joanna Kubler-Kielb; Stephen H Leppla; Robert H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

3.  Human Innate Immune Cells Respond Differentially to Poly-γ-Glutamic Acid Polymers from Bacillus anthracis and Nonpathogenic Bacillus Species.

Authors:  Tanya M Jelacic; Wilson J Ribot; Jennifer Chua; Anne E Boyer; Adrian R Woolfitt; John R Barr; Arthur M Friedlander
Journal:  J Immunol       Date:  2020-01-13       Impact factor: 5.422

4.  Evaluation of the house fly Musca domestica as a mechanical vector for an anthrax.

Authors:  Antonio Fasanella; Silvia Scasciamacchia; Giuliano Garofolo; Annunziata Giangaspero; Elvira Tarsitano; Rosanna Adone
Journal:  PLoS One       Date:  2010-08-17       Impact factor: 3.240

5.  The genome of a Bacillus isolate causing anthrax in chimpanzees combines chromosomal properties of B. cereus with B. anthracis virulence plasmids.

Authors:  Silke R Klee; Elzbieta B Brzuszkiewicz; Herbert Nattermann; Holger Brüggemann; Susann Dupke; Antje Wollherr; Tatjana Franz; Georg Pauli; Bernd Appel; Wolfgang Liebl; Emmanuel Couacy-Hymann; Christophe Boesch; Frauke-Dorothee Meyer; Fabian H Leendertz; Heinz Ellerbrok; Gerhard Gottschalk; Roland Grunow; Heiko Liesegang
Journal:  PLoS One       Date:  2010-07-09       Impact factor: 3.240

6.  Treatment of experimental anthrax with recombinant capsule depolymerase.

Authors:  Angelo Scorpio; Steven A Tobery; Wilson J Ribot; Arthur M Friedlander
Journal:  Antimicrob Agents Chemother       Date:  2007-12-26       Impact factor: 5.191

7.  Constant domains influence binding of mouse-human chimeric antibodies to the capsular polypeptide of Bacillus anthracis.

Authors:  Mark A Hubbard; Peter Thorkildson; Thomas R Kozel; David P AuCoin
Journal:  Virulence       Date:  2013-07-17       Impact factor: 5.882

8.  Stereo-selective binding of monoclonal antibodies to the poly-γ-D-glutamic acid capsular antigen of Bacillus anthracis.

Authors:  Mark A Hubbard; Peter Thorkildson; William H Welch; Thomas R Kozel
Journal:  Mol Immunol       Date:  2013-04-17       Impact factor: 4.407

Review 9.  Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax.

Authors:  Anette Schneemann; Marianne Manchester
Journal:  Future Microbiol       Date:  2009-02       Impact factor: 3.165

10.  Rapid detection of the poly-gamma-D-glutamic acid capsular antigen of Bacillus anthracis by latex agglutination.

Authors:  David P AuCoin; Marjorie D Sutherland; Ann L Percival; C Rick Lyons; Julie A Lovchik; Thomas R Kozel
Journal:  Diagn Microbiol Infect Dis       Date:  2009-04-02       Impact factor: 2.803

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.